Showing 681-690 of 1100 results for "".
- CeraVe and Dr. Amy Brodsky to Observe Sun Safety Day at Wrigley Fieldhttps://practicaldermatology.com/news/cerave-and-dr-amy-brodsky-to-observe-sun-safety-day-at-wrigley-field/2461235/CeraVe is sponsoring Sun Safety Day at Wrigley Field this weekend with event founder, Chicago-based board-certified dermatologist, Amy Brodsky, MD. Melanoma diagnosis in young adults is up 253% in the last 40 years. Sun damage in childhood is one of the leading factors o
- Nu Skin Kicks Off Its Global Day of Service with Projects for Childrenhttps://practicaldermatology.com/news/nu-skin-kicks-off-its-global-day-of-service-with-projects-for-children/2461233/Nu Skin is hosting its 19th annual Force for Good Day to support its global humanitarian efforts. To celebrate the company's founding and to give back to local communities, each Nu Skin region sets aside a day to participate in service projects as part of its mission to b
- FDA Approves Olumiant from Eli Lilly for Alopecia Areatahttps://practicaldermatology.com/news/fda-approves-olumiant-from-eli-lilly-for-alopecia-areata/2461231/Olumiant (baricitinib) from Eli Lilly and Company is approved to treat adult patients with severe alopecia areata. FDA action marks the first approval of a systemic treatment for alopecia areata. Olumiant is
- Crown to Acquire Aesthetic Product Portfolio from Eclipsehttps://practicaldermatology.com/news/crown-to-acquire-aesthetic-product-portfolio-from-eclipse/2461208/Crown Laboratories will acquire the global aesthetics-focused assets of Eclipse. The acquisition expands Crown's aesthetics' product portfolio and enhances Crown's overall value proposition as a global leader in science-based aesthetic skincare solutions. "We
- CHMP Recommends Approval of Lilly and Incyte's Olumiant for Severe AAhttps://practicaldermatology.com/news/chmp-recommends-approval-of-lilly-and-incytes-olumiant-for-severe-aa/2461204/The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly and Company and Incyte’s Olumiant (baricitinib) for the treatment of adults with severe alopecia areata (AA). This opinion marks the fir
- Ophthalmologist Ashley Brissette, MD Launches Eye Area Skincare Linehttps://practicaldermatology.com/news/ophthalmologist-ashley-brissette-md-launches-eye-area-skincare-line/2461193/Daily Practice, the new eye care line by ophthalmologist Ashley Brissette, MD, has launched with a hero product—Eye Revive. Having worked as an ophthalmologist for six years, New York City-based Dr. Brissette says she recognized a growing trend of
- DermTech Seeks to #Stickit2Melanomahttps://practicaldermatology.com/news/dermtech-seeks-to-stickit2melanoma/2461184/DermTech is bringing back its #Stickit2Melanoma campaign in honor of Melanoma and Skin Cancer Awareness Month. First launched in 2021, the campaign supports DermTech’s core mission to help end deaths from melanoma through early and reliable detection. For every
- Cutera Hosts AviClear Webinar This Weekhttps://practicaldermatology.com/news/cutera-hosts-aviclear-webinar-this-week/2461178/Cutera hosts the first webinar for AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne, this week. Dermatologists Jeffrey S. Dover, MD, FRCPC and Julie C. Harper, MD will discuss the latest advancement in the treatment of acn
- FDA Approves Sol-Gel Technologies' and Galderma's Epsolay for Rosaceahttps://practicaldermatology.com/news/fda-approves-sol-gel-technologies-and-galdermas-epsolay-for-rosacea/2461170/The FDA has approved Sol-Gel Technologies' Epsolay, a proprietary cream formulation of benzoyl peroxide, 5%, for the treatment of inflammatory lesions of rosacea in adults. The benzoyl peroxide in Epsolay is encapsulated within silica-based patented microcapsules. The silica-based s
- Cutera to Celebrate AviClear Launch at ASLMShttps://practicaldermatology.com/news/cutera-to-celebrate-aviclear-launch-at-aslms/2461165/Cutera is celebrating the launch of AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne, during the ASLMS meeting in San Diego. ASLMS attendees are invited to the celebration for the launch of AviClear on Thursday, April 28,